Objectives: Accumulating evidence supports the hypothesis that HLA antibodies play an important role in early renal allograft injury. However, the effects of HLA antibodies on long-term graft survival are still poorly understood. In this study, we examined the impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts for 10 years. Material and Methods: In this retrospective study, long-term renal recipients were defined as kidney transplant recipients who had normally functioning renal grafts (serum creatinine level <2.0 mg/dl) for 10 years. Posttransplant serum samples from a total of 92 long-term renal allograft recipients on cyclosporine-based triple maintenance drug therapy (121.6 ± 0.886 months) were screened for the specificities of anti-HLA antibodies. The results of HLA antibodies before the transplantation, assessed using the same test method, were compared with those after their transplantations. Moreover, these 92 patients who received cadaveric renal transplant between January 2000 and December 2002 were followed up for about 10 years (range 107-135 months). Results: 27 patients had HLA-I antibodies and 16 patients had HLA-II antibodies before the transplantation, whereas 12 patients had HLA-I antibodies and 18 patients had HLA-II antibodies after the transplantation. Moreover, the types of HLA antibodies were different from those found before the transplantation. In these renal recipients with functioning renal grafts, the estimated glomerular filtration rate was 66.52 ± 14.52 ml/min/1.73 m2 in the HLA antibody-positive group (n = 23) and 69.09 ± 25.54 ml/min/1.73 m2 negative in the HLA antibody-negative group (n = 69, p > 0.05). Three patients (3.26%) (3 out of 92) had donor-specific anti-HLA antibodies (DSA). The frequency of DSA in this study was lower than that in the general Chinese Han renal recipient population. Conclusions: We find that all HLA antibodies in the long-term renal grafts are newly formed after the transplantation. The HLA antibody status has little impact on the renal graft function in the long-term renal recipients.

Keywords:
Kidney transplantation, HLA antibody, Graft survival
1.
Bartel G, Schwaiger E, Bohmig GA: Prevention and treatment of alloantibody-mediated kidney transplant rejection. Transpl Int 2011;24:1142-1155.
2.
Leffell MS, Zachary AA: Anti-allograft antibodies: some are harmful, some can be overcome, and some may be beneficial. Discov Med 2010;9:478-484.
3.
Loupy A, Suberbielle-Boissel C, Hill GS, Lefaucheur C, Anglicheau D, Zuber J, et al: Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009;9:2561-2570.
4.
Iwasaki K, Miwa Y, Haneda M, Uchida K, Nakao A, Kobayashi T: Significance of HLA class I antibody-induced antioxidant gene expression for endothelial cell protection against complement attack. Biochem Biophys Res Commun 2010;391:1210-1215.
5.
Terasaki PI, Ozawa M: Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004;4:438-443.
6.
Everly MJ, Terasaki PI: Monitoring and treating posttransplant human leukocyte antigen antibodies. Hum Immunol 2009;70:655-659.
7.
Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, et al: Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012;12:563-570.
8.
Naemi FM, Ali S, Kirby JA: Antibody-mediated allograft rejection: the emerging role of endothelial cell signalling and transcription factors. Transpl Immunol 2011;25:96-103.
9.
Hidalgo LG, Campbell PM, Sis B, Einecke G, Mengel M, Chang J, et al: De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009;9:2532-2541.
10.
Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, et al: Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009;87:1555-1561.
11.
Gill JS, Landsberg D, Johnston O, Shapiro RJ, Magil AB, Wu V, et al: Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. Transplantation 2010;89:178-184.
12.
Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee JH, El-Awar N, Alberu J: ‘Natural' human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008,86:1111-1115.
13.
Zhang Q, Reed EF: Non-MHC antigenic targets of the humoral immune response in transplantation. Curr Opin Immunol 2010;22:682-688.
14.
Everly MJ, Terasaki PI, Trivedi HL: Durability of antibody removal following proteasome inhibitor-based therapy. Transplantation 2012;93:572-577.
15.
Zhihong L, Janming T, Zhilin H, Yu F, Yande D: Impact of donor-specific antibodies on kidney graft short-term survival. Chin J Organ Transplant 2003;24:356-358.
16.
Xia G, Min-ying T, Qing-hua W, Le-le S, Jin-quan C, Shun-liang J, et al: Application of single antigen antibody test in living-relative renal transplantation. Chin J Organ Transplant 2011;32:596-599.
17.
Ntokou IS, Iniotaki AG, Kontou EN, Darema MN, Apostolaki MD, Kostakis AG, et al: Long-term follow-up for anti-HLA donor-specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules. Transpl Int 2011;24:1084-1093.
18.
Thaunat O: Humoral immunity in chronic allograft rejection: puzzle pieces come together. Transpl Immunol 2012;26:101-106.
19.
Khater N, Khauli R: Pseudorejection and true rejection after kidney transplantation: classification and clinical significance. Urol Int 2013;90:373-380.
20.
Everly MJ, Everly JJ, Arend LJ, Brailey P, Susskind B, Govil A, et al: Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009;9:1063-1071.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.